Updated ASCO guidelines for pleural mesothelioma refine surgery use, recommend immunotherapy, genetic testing, and improve ...

Researchers are testing whether the Clarity ctDNA test can reliably identify patients who do just as well long term with less chemotherapy.

Foresight Diagnostics, which provides ultra-sensitive minimal residual disease (MRD) detection technology, today announced the launch of the PRECISE-HL clinical trial with the University of Washington ...

Researchers at the Icahn School of Medicine at Mount Sinai have made an important discovery that could help doctors choose ...

In patients with advanced melanoma, nivolumab/relatlimab combination therapy shows a cutaneous irAEs prevalence of 21.5%, ...

David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...

Perspective Therapeutics, Inc.’s CATX share price has dipped by 11.51%, which has investors questioning if this is right time ...

A comprehensive study of effective responses as well as resistant responses to a kidney cancer anti-PD-1 therapy found ...

Combination treatment with nivolumab and cabozantinib provides long-term benefits over sunitinib in patients with advanced RCC, according to final results from the CheckMate 9ER trial.

In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high ...

IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential ...

Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...